Table 3 All Adverse events in relation to NRS, SF-MNA and MNA
NRS | T1 | T2 | |||||
Risk for malnutrition / no risk | + | – | p | + | – | p | |
all | Adverse events | 53.2% (25) | 35.5% (108) | 22.6% (7) | 9.3% (20) | ||
No adverse events | 46.8% (22) | 64.5% (196) | 0.02 | 77.4% (24) | 90.7% (195) | 0.03 | |
n total | 47 | 304 | 31 | 215 | |||
pAP | Adverse events | 40.6% (13) | 32.7% (82) | 13.6% (3) | 8.2% (15) | ||
No adverse events | 59.4% (19) | 67.3% (169) | 0.37 | 86.4% (19) | 91.8% (167) | 0.40 | |
n total | 32 | 251 | 22 | 182 | |||
rAP | Adverse events | 80.0% (12) | 49.1% (26) | 44.4% (4) | 15.2% (5) | ||
No adverse events | 20.0% (3) | 50.9% (27) | 0.03 | 55.6% (5) | 84.8% (28) | 0.06 | |
n total | 15 | 53 | 9 | 33 | |||
SF-MNA | T1 | T2 | |||||
Risk for malnutrition / no risk | + | – | p | + | – | p | |
all | Adverse events | 46.4% (39) | 35.2% (94) | 17.9% (10) | 8.9% (17) | ||
No adverse events | 53.6% (45) | 64.8% (173) | 0.06 | 82.1% (46) | 91.1% (173) | 0.06 | |
n total | 84 | 267 | 56 | 190 | |||
pAP | Adverse events | 39.4% (26) | 31.8% (69) | 12.8% (6) | 7.6% (12) | ||
No adverse events | 60.6% (40) | 68.2% (148) | 0.25 | 87.2% (41) | 92.3% (145) | 0.28 | |
n total | 66 | 217 | 47 | 157 | |||
rAP | Adverse events | 72.2% (13) | 50.0% (25) | 44.4% (4) | 15.2% (5) | ||
No adverse events | 27.8% (5) | 50.0% (25) | 0.10 | 55.6% (5) | 84.8% (28) | 0.06 | |
n total | 18 | 50 | 9 | 33 | |||
MNA | T1 | T2 | |||||
Risk for malnutrition / no risk | + | – | p | + | – | p | |
all | Adverse events | 49.0% (47) | 33.7% (86) | 17.5% (11) | 8.7% (16) | ||
No adverse events | 51.0% (49) | 66.3% (169) | 0.01 | 82.5% (52) | 91.3% (167) | 0.06 | |
n total | 96 | 255 | 63 | 183 | |||
pAP | Adverse events | 43.2% (33) | 29.9% (62) | 15.1% (8) | 6.6% (10) | ||
No adverse events | 56.8% (43) | 70.1% (145) | 0.03 | 8.9% (45) | 93.4% (141) | 0.06 | |
n total | 76 | 207 | 53 | 141 | |||
rAP | Adverse events | 70.0% (14) | 50.0% (24) | 30.0% (3) | 18.8% (6) | ||
No adverse events | 30.0% (6) | 50.0% (24) | 0.13 | 70.0% (7) | 81.2% (26) | 0.45 | |
n total | 20 | 48 | 10 | 32 | |||